Nanobiotix (NBTX) Receives a Buy from Kepler Capital
In a report issued on June 8, David Evans from Kepler Capital maintained a Buy rating on Nanobiotix (NBTX), with a price target of EUR26.00. The company’s shares closed last Wednesday at $16.35.
According to TipRanks.com, Evans is a 4-star analyst with an average return of 8.7% and a 67.3% success rate. Evans covers the Healthcare sector, focusing on stocks such as Quantum Genomics, Innate Pharma, and Crossject SA.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nanobiotix with a $31.65 average price target.
See today’s analyst top recommended stocks >>
Nanobiotix’s market cap is currently $599M and has a P/E ratio of -10.30. The company has a Price to Book ratio of 7.01.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nanobiotix SA is a late-stage clinical company engaged in developing and selling nanomedicine for the treatment of cancer. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. The company’s products include NBTXR3, a preclinical research program for cancer immunotherapies.